Ítem
Acceso Abierto

Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: The pan-american collaborative retina study

Mostrar el registro sencillo de la publicación
dc.creatorArevalo, J. Fernandospa
dc.creatorSánchez, Juan G.spa
dc.creatorWu, Lihtehspa
dc.creatorBerrocal, Maria H.spa
dc.creatorAlezzandrini, Arturo A.spa
dc.creatorRestrepo, Nataliaspa
dc.creatorMaia, Mauriciospa
dc.creatorFarah, Michel E.spa
dc.creatorBrito, Miguelspa
dc.creatorDíaz-Llopis, Manuelspa
dc.creatorRodríguez, Francisco J.spa
dc.creatorReategui, Guillermospa
dc.creatorIturralde-Iraola, Juanspa
dc.creatorUdaondo-Mirete, Patriciaspa
dc.creatorGroup, Pan-American Collaborative Retina Studyspa
dc.creator.OrganizationalPan-American Collaborative Retina Study Group (PACORES)
dc.date.accessioned2020-05-25T23:57:44Z
dc.date.available2020-05-25T23:57:44Z
dc.date.created2010spa
dc.description.abstractPurpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2.5 mg) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design: Retrospective, multicenter, interventional, comparative case series. Participants: We reviewed the clinical records of 180 consecutive patients (207 eyes) with subfoveal CNV secondary to AMD at 9 centers from 8 countries. Methods: Patients were treated with at least 1 injection of IVB 1.25 mg (124 eyes [59.9%]) or 2.5 mg (83 eyes [40.1%]). Patients underwent ETDRS BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and 1-, 3-, 6-, 12-, and 24-month visits. Main Outcome Measures: Changes in BCVA and OCT. Results: The mean age of our patients was 74.3±7.5 years. The mean number of IVB injections per eye was 5.1 (range, 124 injections). In the 1.25 mg group, baseline BCVA improved from 20/235 (logarithm of the minimum angle of resolution [logMAR] 1.07) to 20/172 (logMAR 0.92) at 24 months (P less than 0.0001). Similar BCVA changes were observed in the 2.5 mg group. At baseline, the mean central macular thickness (CMT) by OCT in the 1.25 mg group was 308.4±127.52 ?m, which was reduced to 269.35±97.92 ?m, 262.1±94.81 ?m, 264.03±97.06 ?m, 245.91±89.52 ?m, and 249.27±89.14 ?m at 1, 3, 6, 12, and 24 months, respectively (P less than 0.0001). Similar changes were observed in the 2.5 mg group. In the 2.5 mg group, systemic complications included 2 new cases (2.6%) of arterial hypertension, 1 case (1.3%) of stroke, and 1 case (1.3%) of death. Conclusions: Primary IVB at a dose of 1.25 or 2.5 mg seems to provide stability or improvement in BCVA, OCT, and FA in subfoveal CNV secondary to AMD at 24 months. Our results show no significant difference regarding BCVA with IVB at doses of 1.25 or 2.5 mg. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2010 American Academy of Ophthalmology.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.ophtha.2010.01.056
dc.identifier.issn15494713
dc.identifier.issn01616420
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22732
dc.language.isoengspa
dc.publisherElsevier Inc.spa
dc.relation.citationEndPage1981.e1
dc.relation.citationIssueNo. 10
dc.relation.citationStartPage1974
dc.relation.citationTitleOphthalmology
dc.relation.citationVolumeVol. 117
dc.relation.ispartofOphthalmology, ISSN:15494713, 01616420, Vol.117, No.10 (2010); pp. 1974-1981.e1spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84928585502&doi=10.1016%2fj.ophtha.2010.01.056&partnerID=40&md5=94617519395820899a93b382b5aad0f1spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordmonoclonaleng
dc.subject.keywordhumanizedeng
dc.subject.keywordMonoclonal antibodyspa
dc.subject.keywordVasculotropin aspa
dc.subject.keywordVegfa proteineng
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordArticlespa
dc.subject.keywordCataractspa
dc.subject.keywordDrug dose comparisonspa
dc.subject.keywordDrug fatalityspa
dc.subject.keywordEndophthalmitisspa
dc.subject.keywordEye examinationspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescence angiographyspa
dc.subject.keywordFollow upspa
dc.subject.keywordHumanspa
dc.subject.keywordHypertensionspa
dc.subject.keywordIntraocular pressurespa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordMedical record reviewspa
dc.subject.keywordOptical coherence tomographyspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRetina macula age related degenerationspa
dc.subject.keywordRetina tearspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordSide effectspa
dc.subject.keywordStrokespa
dc.subject.keywordSubretinal neovascularizationspa
dc.subject.keywordTreatment responsespa
dc.subject.keywordUveitisspa
dc.subject.keywordVisual acuityspa
dc.subject.keywordAntagonists and inhibitorsspa
dc.subject.keywordChoroidal neovascularizationspa
dc.subject.keywordClinical trialspa
dc.subject.keywordComparative studyspa
dc.subject.keywordComplicationspa
dc.subject.keywordInjectionspa
dc.subject.keywordMacular degenerationspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordMulticenter studyspa
dc.subject.keywordPathophysiologyspa
dc.subject.keywordPhysiologyspa
dc.subject.keywordRetina foveaspa
dc.subject.keywordTimespa
dc.subject.keywordVery elderlyspa
dc.subject.keywordVitreous bodyspa
dc.subject.keywordAgedspa
dc.subject.keywordAged, 80 and overspa
dc.subject.keywordAngiogenesis inhibitorsspa
dc.subject.keywordAntibodieseng
dc.subject.keywordAntibodieseng
dc.subject.keywordChoroidal neovascularizationspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescein angiographyspa
dc.subject.keywordFollow-up studiesspa
dc.subject.keywordFovea centralisspa
dc.subject.keywordHumansspa
dc.subject.keywordInjectionsspa
dc.subject.keywordMacular degenerationspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRetrospective studiesspa
dc.subject.keywordTime factorsspa
dc.subject.keywordTomographyeng
dc.subject.keywordVascular endothelial growth factor aspa
dc.subject.keywordVisual acuityspa
dc.subject.keywordVitreous bodyspa
dc.titleIntravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: The pan-american collaborative retina studyspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
1-s2-0-S0161642010001296.pdf
Tamaño:
1.08 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos